Press Release: AOBiome : USPTO Grants AOBiome Therapeutics Composition of Matter Patent for its Clinical Candidate B244

AOBiome: AOB Pharma, Maruho partner to develop B244 for inflammatory ailments

AOBiome: Biorasi, LLC: Biorasi Featured in AOBiome B244 Clinical Study Report in The Lancet's eClinicalMedicine

Press Release: AOBiome : AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical Candidate B244

AOBiome: AOBiome Reaches Key Enrollment Goal For Largest Clinical Trial Ever With A Topical Biotherapeutic

AOBiome: New 30 Patient Study Of AOBiome's New Shelf-Stable Formulation Of Its Ammonia Oxidizing Bacteria (AOB) Shows Reduction Of Itch Levels In Both Pediatric And Adult Subjects Who Suffer From Eczema.

AOBiome: Nature Scientific Reports has published a peer reviewed paper showing important immune response benefits associated with AOBiome's B244 Ammonia Oxidizing Bacteria drug therapy

AOBiome: AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults

Press Release: AOBiome : AOBiome Doses First Patient in Phase 1b Clinical Trial of B244 for the Treatment of Pediatric Atopic Dermatitis

Press Release: AOBiome : AOBiome Therapeutics Expands Intellectual Property Estate with Issuance of U.S. Patent for Use of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Eczema